- Home
- HTH vs NKTR Comparison
HTH vs NKTR Comparison
Compare HTH & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | NKTR |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2003 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HTH | NKTR |
|---|---|---|
| Price | $36.54 | $41.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $41.00 | ★ $141.40 |
| AVG Volume (30 Days) | 299.0K | ★ 1.5M |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | $152,188,000.00 | ★ $307,711,000.00 |
| Revenue This Year | $2.13 | N/A |
| Revenue Next Year | $2.14 | $33.30 |
| P/E Ratio | $28.88 | ★ N/A |
| Revenue Growth | 15.52 | ★ 86.00 |
| 52 Week Low | $30.78 | $33.40 |
| 52 Week High | $40.41 | $109.00 |
Technical Indicators
Market Signals| Indicator | HTH | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 32.74 | 23.56 |
| Support Level | $36.32 | $33.87 |
| Resistance Level | $38.52 | $76.63 |
| Average True Range (ATR) | 0.66 | 3.94 |
| MACD | -0.18 | -1.69 |
| Stochastic Oscillator | 12.34 | 9.22 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.